Description
Anti-HLA-B27 Antibody, Non-Fucosylated (BioBet-995ZP) is a human monoclonal IgG antibody against HLA-B27. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Autoimmune Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced HLA-B27 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
HLA-B27
Full Name
Human Leukocyte Antigen B27
Background
Human Leukocyte Antigen (HLA) B27 (subtypes B*2701-2759) is a class I surface antigen encoded by the B locus in the major histocompatibility complex (MHC) on chromosome 6 and presents antigenic peptides (derived from self and non-self antigens) to T cells. HLA-B27 is strongly associated with ankylosing spondylitis (AS), and other associated inflammatory diseases referred to as "spondyloarthropathies".
Alternative Names
HLA-B27; Human Leukocyte Antigen B27
UniProt ID
Q9UK05
Cellular Localization
Plasma membrane, Endoplasmic reticulum
Involvement in Disease
Diseases associated with HLA-B include Severe Cutaneous Adverse Reaction and Spondyloarthropathy 1.
Related Pathways
Its related pathways are Antigen processing-Cross presentation and Actin Nucleation by ARP-WASP Complex.
Function
The antigen presents major histocompatibility complex I (MHCI) molecules. The complex B2M/β2 microglobulin shows the α-β T cell receptor (TCR) HLA-B-restricted cd8 + T cells recognized by the main virus and tumor-derived peptide antigen presenting cells, which guide the antigen T cell immune response and eliminate infection Or transformed cells. There may also be self-peptides derived from secreted proteins or membrane protein signal sequences, although T cells directed against these peptides are usually inactivated to prevent self-reactions. Both peptides and MHC molecules can be recognized by TCR. Peptides are responsible for the good specificity of antigen recognition, and MHC residues are responsible for T cell MHC restriction. A typical intracellular peptide antigen is composed of 8-13 amino acids and is produced by intracellular proteolysis of constitutive proteasomes and immune proteasomes induced by ifgn. It can bind to different peptides containing allele-specific binding motifs, which are mainly determined by anchor residues at positions 2 and 9.
Field of research
Immune System antibody
Post-translational modifications
Polyubiquitinated in a post ER compartment by interaction with human herpesvirus 8 MIR1 protein. This targets the protein for rapid degradation via the ubiquitin system (By similarity).
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
HD4
Description
The antibody directed against hla-b27 homodimers are useful in the diagnosis and treatment of HLA-B27 mediated conditions, particularly those associated with B272, the spondylarthritides, a group of related diseases including ankylosing spondylitis (AS) and reactive arthritis (ReA or Reiter's syndrome).
Antibody Indication
Autoimmune Diseases
